Clearmind Medicine Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board
October 14, 2021 08:00 ET
|
Clearmind Medicine
TORONTO, Ontario, Oct. 14, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
Clearmind Medicine Partners With Clinipace to Commence Processes Towards FDA Approval
October 07, 2021 08:00 ET
|
Clearmind Medicine
Toronto, Ontario, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
Tripsitter.Clinic Launches At-Home Ketamine Therapy Service Across the U.S.
September 01, 2021 11:32 ET
|
TripSitter.Clinic
AUSTIN, Texas, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Tripsitter Clinic Corp. is pleased to announce that the company is now accepting and seeing patients throughout the states of California,...
Mycotopia Therapies Signs Agreement With Havn Life Sciences For Purchase of Psilocybin SPP
August 25, 2021 08:00 ET
|
Mycotopia Therapies Inc.
MIAMI, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies, Inc. (OTC Pink: TPIA) (the “Company”), a company focused on psychedelic therapies, announced today it has entered into a Psilocybin...
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Kelsey Ramsden, Co-Founder & CEO of Mind Cure Health Inc.
August 19, 2021 08:17 ET
|
InvestorBrandNetwork (IBN)
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
Ehave acquires License covering G-20 Countries for all Psychedelic use, AI-Powered Telehealth Technology To Capture Physiological Vitals From Vastmindz; Prepares To Run Testing On Dashboard
August 11, 2021 08:30 ET
|
Ehave
MIAMI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has...
Ehave Partners with Globally Recognized University to Target Hallucinogen Persisting Perception Disorder (HPPD)
August 04, 2021 08:30 ET
|
Ehave
MIAMI, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, today announced a...
Hallucinogen Persisting Perception Disorder (HPPD) Research Initiated By Ehave
July 29, 2021 08:30 ET
|
Ehave
HPPD is a psychiatric disorder characterized by the persisting presence of sensory disturbances, most commonly visual, that resemble those produced by the use of hallucinogenic substances. Ehave...
Ehave Releases Additional Information On Partnership With Cutting Edge Data Provider As It Expands Capabilities
July 13, 2021 08:30 ET
|
Ehave
MIAMI, July 13, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced a partnership with...
Ehave Hires Institutional Review Board (IRB) As It Solidifies Partnership With Tristar Wellness Launching Ketamine Clinical Trials In Miami
July 09, 2021 09:30 ET
|
Ehave
MIAMI, July 09, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today the Company...